We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

User:Carson Powers/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 20: Line 20:
===''Receptor Binding Domains''===
===''Receptor Binding Domains''===
-
<scene name='10/1076041/Spike_protein_only/1'>The spike protein is a homotrimer with three RBDs which contains the active site on the protein. </scene> The spike protein’s RBDs attach to the human ACE2 receptor.
+
The spike protein is a homotrimer with <scene name='10/1076041/Spike_protein_only/1'>three RBDs, containing the active site. </scene> The spike protein’s RBD is the region where it attaches to the human ACE2 receptor.
==ACE2 Receptor==
==ACE2 Receptor==
-
<scene name='10/1076041/Ace2_only/2'>Ace Receptor</scene>
+
<scene name='10/1076041/Ace2_only/2'>ACE2,</scene> the natural receptor for the spike protein, is a membrane-bound protein located in the lungs and made up of 805 amino acids. <scene name='10/1076041/Ace2_interactions/3'>Its active site is located within a single extracellular N-terminal domain. Residues 26-43 in this region form an alpha helix which makes the majority of interactions with the RBD of the spike protein. These interactions are stabilized by hydrogen bonding and van der Waals forces. </scene>
-
===ACE2 Binding Residues===
 
-
<scene name='10/1076041/Ace2_interactions/3'>Binding Interactions</scene>
 
 +
=Mini Protein Inhibitors=
==AHB2==
==AHB2==
-
<scene name='10/1076041/Ahb2_only/2'>AHB2</scene>
+
<scene name='10/1076041/Ahb2_only/2'>AHB2</scene>is a stable miniprotein inhibitor that competes with the ACE2 receptor. It was developed using the Rosetta blueprint builder that incorporates the alpha helix in ACE2 (residues 23-46) into small, stable protein scaffolds. <scene name='10/1076041/Ahb2_interactions/1'>Along with making similar interactions with the spike protein, AHB2 includes additional interactions to increase its affinity.</scene> This allows it to compete with the ACE2 receptor effectively, preventing it from binding with the spike protein and the virus from infecting host cells.
-
===AHB2 Interactions===
 
-
<scene name='10/1076041/Ahb2_interactions/1'>AHB2 Interactions</scene>
 
==LCB==
==LCB==
 +
 +
<scene name='10/1076042/Overall_lcb1_spike/3'>LCB1</scene>is a fully synthetic three-helix mini protein that acts as a competitive inhibitor, competing with ACE2 to bind to the spike protein. Unlike ABH2, <scene name='10/1076041/Lcb1_interactions/2'>a de novo design approach was taken to design LCB1, making it more compact with optimal interactions with the RBD.</scene>
 +
 +
Another mini protein inhibitor, <scene name='10/1076041/Lcb3_only/1'>LCB3,</scene> was developed using the same computational method as LCB1 and <scene name='10/1076042/Lcb3xspikecorlabel_intxn/1'>binds to the same region of the RBD, except in the opposite direction.</scene> However, LCB1 has more surface area and fits more precisely with its computational model, giving it a slightly higher binding affinity.
 +
 +
The LCBs have a significantly higher affinity for the spike RBD and are smaller and more stable than traditional antibodies. Their reduced size allows these molecules to tightly pack more interactions in the active site as well as improve their ability to enter the respiratory system.
 +
 +
 +
===LCB1===
===LCB1===

Revision as of 02:07, 14 April 2025

De novo miniprotein Covid therapeutic

LCB1 bound to spike protein. LCB1 is colored pink and shown in cartoon. The spike protein is colored by chain and shown by its surface. PDB file: 7jzl

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

Carson Powers

Personal tools